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Available online 4 May 2016Objective: To investigatewhether increasing plasmadonepezil concentration further improves cognitive function
and neuropsychiatric symptoms without compromising safety in patients with dementia with Lewy bodies
(DLB).
Methods:We analyzed data from a 12-week phase 3 trial of donepezil (5 and 10 mg/day) in patients with DLB.
The contribution of factors affecting plasma donepezil concentrationwas evaluatedusingmultivariate regression
analysis. The relationships between plasma donepezil concentration and efﬁcacy (cognitive function as mea-
sured by the Mini-Mental State Examination [MMSE], hallucinations and cognitive ﬂuctuation), or safety
(blood pressure, pulse rate, body weight, and parkinsonism asmeasured by the Uniﬁed Parkinson's Disease Rat-
ing Scale part III) were assessed by scatterplots and Pearson correlation.
Results: The data of 87 patients were used in the analyses. Plasma donepezil concentration increased proportion-
ally with increasing dose from 5 to 10 mg/day. The dose (contribution rate: 0.39, p b 0.0001) and age (contribu-
tion rate: 0.12, p = 0.0003) were statistically signiﬁcant contributing factors affecting plasma donepezil
concentration. Plasma donepezil concentration correlated signiﬁcantly with improvement of MMSE score
(p = 0.040), but no signiﬁcant correlations were found with the change in other tested parameters.
Conclusions: Plasma donepezil concentration correlated positively with change in cognitive function without af-
fecting safety, andwas affectedmainly by dose and to a lesser extent by age. Therefore, for patients inwhomsafe-
ty concerns are not found at donepezil 5 mg/day, increasing the dose to 10 mg/day to increase plasma
concentration is worthwhile to further improve cognitive function.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Efﬁcacy1. Introduction
Dementia with Lewy bodies (DLB) is the secondmost common type
of dementia after Alzheimer's dementia (AD) [1]. Core features of DLB
include parkinsonism and neuropsychiatric symptoms such as halluci-
nations and cognitive ﬂuctuation, as well as cognitive impairment [2].
Cholinesterase inhibitors (ChEIs) are used to treat the symptoms of
DLB based on its neurochemical features: loss of cholinergic neurons
and choline acetyltransferase activity, but well-preserved postsynaptic
cortical muscarinic receptors [3,4,5]. Galantamine, rivastigmine, andral Neurology and Cognitive
dicine, 2-1 Seiryo-machi, Aoba-
. This is an open access article underdonepezil have been shown to be effective in treating DLB patients in
several trials [6,7,8,9,10,11,12,13,14,15], and donepezil has been ap-
proved for treating DLB in Japan. A 12-week, phase 2, randomized con-
trolled trial (RCT) of donepezil in DLB patients demonstrated improved
cognitive function (evaluated by the Mini-Mental State Examination
[MMSE]) and neuropsychiatric symptoms (evaluated by Neuropsychi-
atric Inventory [NPI]) at both 5 and 10 mg/day [11]. In the subsequent
open-label extension (OLE) study, 5mg/day donepezil waswell tolerated
and improved cognitive function and neuropsychiatric symptoms for up
to 52 weeks [8]. In a phase 3 RCT of donepezil in DLB patients, cognitive
function was signiﬁcantly improved by 10 mg/day donepezil without se-
rious safety concerns, although improvement of neuropsychiatric symp-
toms over placebo was not conﬁrmed, owing to the unexpectedly high
improvement in the placebo group [9]. The cognitive function improve-
ment continued up to 52 weeks without an increased risk of clinicallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OLE study [12].
Improvement of cognitive function and neuropsychiatric symptoms
by donepezil appeared to be dose-dependent in the above-mentioned
RCTs. However, to the best of our knowledge, the pharmacokinetics
(PK), the relationship between plasma concentration and efﬁcacy, and
the relationship between plasma concentration and safety of donepezil
have not been assessed in DLB patients. Additionally, there are clinical
concerns in increasing the ChEI dose in DLB patients, because in theory,
ChEIs may cause bradyarrhythmia and worsening of parkinsonism [16,
17,18,19]. These concerns and lack of data might deter physicians
from increasing the ChEI dose in patients whose cognitive function
and/or neuropsychiatric symptoms need further improvement.
To investigate whether higher plasma donepezil concentrations fur-
ther improve cognitive function and neuropsychiatric symptoms with-
out compromising the safety of DLB patients, we assessed the
relationship between plasma donepezil concentration and efﬁcacy or
safety parameters, using data derived from the phase 3 RCT of donepezil
[9].
2. Methods
2.1. Data source
We analyzed data from the 12-week RCT phase of the phase 3 study
of donepezil inDLBpatients [9]. The original studywas a 52-week study,
which integrated a placebo-controlled, 16-week RCT phase (consisting
of a 12-week conﬁrmatory phase followed by a 4-week transition peri-
od) and a 36-week OLE phase [9,12]. Patients were randomly allocated
to the placebo, 5 mg/day donepezil, or 10 mg/day donepezil groups. In
both donepezil groups, 3 mg/day was administered for the ﬁrst
2 weeks. For the 10mg group, the dose was titrated to 5 mg/day for an-
other 4weeks prior to administering 10mg/day. Eligibility criteria were
as follows: (1) outpatients aged ≥50 years, (2) diagnosis of probable
DLB according to the consensus diagnostic criteria [2], (3) mild to
moderate-severe dementia (10–26 on theMMSE and a Clinical Demen-
tia Rating of ≥0.5), and (4) presence of neuropsychiatric symptoms
(NPI-plus [12 items with original NPI-10 items, an item of sleep [20,
21, and an item of cognitive ﬂuctuation reported as Cognitive Fluctua-
tion Inventory (CFI) [22,13]] ≥ 8 and NPI-2 [composite score of NPI hal-
lucinations and CFI] [11] ≥ 1). Exclusion criteria were: (1) Parkinson's
disease thatwas diagnosed at least 1 year prior to the onset of dementia,
(2) focal vascular lesions visible on MRI or CT scans that might cause
cognitive impairment, (3) other neurological or psychiatric diseases,
(4) systolic hypotension (b90 mm Hg), (5) bradycardia (b50 bpm),
(6) sick sinus syndrome, (7) atrial or atrioventricular conduction
block, (8) QT interval prolongation (≥450 ms), (9) hypersensitivity to
donepezil or piperidine derivatives, (10) severe parkinsonism (Hoehn
and Yahr stage ≥ IV) [23], and (11) treatment with ChEIs or any investi-
gational drug within 3 months prior to screening. ChEIs, antipsychotics,
and anti-Parkinson drugs other than levodopa or dopamine agonists
were prohibited during the study. The following subjectswere excluded
from the present PK/pharmacodynamic analysis; those who did not
take the study drug the day before plasma collection, those who took
study drug just before plasma collection, and thosewhose drug compli-
ance rate of b75%. The trial was conducted in 72 sites throughout Japan
from 2011 to 2013 in accordance with the principles of the Declaration
of Helsinki. The protocolwas approved by the institutional reviewboard
at each participating center. Written informed consent was obtained
from the patients (if at all possible) and from the primary caregiver.
2.2. Plasma concentration measurement
Plasma concentrationwasmeasured in patientswhohad at least one
plasma sample collected at a steady state. Plasma was collected after 4,
8, and 12 weeks of treatment before taking donepezil, or at the time ofdiscontinuation. Plasma donepezil concentrations were analyzed using
a validated liquid chromatography–tandem mass spectrometry (LC–
MS/MS) method. Plasma donepezil concentrations of the placebo
group were excluded from the analysis.
2.3. Factors affecting plasma donepezil concentration
The contributing factors affecting plasma donepezil concentration
were explored using a multivariate regression analysis after selecting
the factors to be included in the model. These factors were: dose (5
and 10 mg/day), patient demographics (sex, age, weight, CYP2D6 phe-
notype), and baseline characteristics (aspartate aminotransferase
[AST], alanine aminotransferase [ALT], total bilirubin, albumin, alkaline
phosphatase [ALP], creatinine clearance, concomitant CYP2D6 inhibitor,
concomitant CYP3A4 inhibitor/inducer). The clinical laboratory data
were categorized as normal or abnormal. One of the correlated variables
was selected for multicollinearity analysis.
2.4. Exposure–response analysis
To investigate the relationship between plasma donepezil concen-
tration and efﬁcacy/safety, we analyzed patients who received
donepezil for at least 4 weeks (3 mg/day for 2 weeks followed by
5mg/day for 2 weeks), andwho had one or more data of efﬁcacy/safety
parameters assessed at the same time point as plasma donepezil
collection.
MMSE and NPI-2 scores, co-primary endpoints of the phase 3 RCT,
were selected as efﬁcacy parameters in this analysis. These were mea-
sured at Weeks 0, 4, 8, and 12, or at the time of discontinuation. The
MMSE score was used to evaluate cognitive impairment. Scores ranged
from0 to 30,with higher scores indicating better cognitive function. The
NPI-2 score was calculated as the sum of the hallucinations and cogni-
tiveﬂuctuation scores. Scores ranged from 0 to 24, with lower scores in-
dicating improved neuropsychiatric symptoms.
Blood pressure (systolic or diastolic), pulse rate, body weight, and
the Uniﬁed Parkinson's Disease Rating Scale (UPDRS) part III [24]
were selected as safety parameters. These were measured at Weeks
0, 4, 8, and 12, or at the time of discontinuation, except UPDRS part
III, which was measured at Weeks 0 and 12, or at the time of discon-
tinuation, and evaluated the severity of parkinsonian symptoms.
Scores ranged from 0 to 108, denoting “no” to “severe” symptoms,
respectively.
Exposure–response analysis was performed using plasma donepezil
concentration and changes from baseline of efﬁcacy/safety parameters
at Week 12, the last observation carried forward (LOCF), as responses.
A scatter plot was used to illustrate the relationship between donepezil
plasma concentrations and changes in efﬁcacy/safety values atWeek 12
(LOCF). After this, relationships between plasma concentrations and pa-
rameters were assessed by Pearson correlation. Statistical tests were
two-tailed, and conducted with a signiﬁcance level of 0.05.
3. Results
3.1. Patients
Overall, 87 patients (5mg/day, 39; 10mg/day, 48) were included in
the exploratory analyses. Patient baseline demographic characteristics
are shown in Table 1. The mean (standard deviation, SD) age was 78.3
(6.2) years, themean bodyweightwas 51.6 (9.7) kg and 56.3% of partic-
ipants were female. The baseline MMSE scores were 20.3 (4.5); NPI-2,
7.3 (4.7); and UPDRS part III, 19.7 (12.1).
3.2. Donepezil plasma concentration
Plasma donepezil concentrations at Weeks 4, 8 and 12 are shown in
Fig. 1. The mean (SD) plasma concentration (ng/mL) at Week 12 was
Table 1
Patient baseline characteristics and demographics (n = 87).
Mean(SD)
or n (%)
Median Minimum–maximum
MMSE score 20.3 (4.5) 21.0 10–26
NPI-2 score 7.3 (4.7) 6.0 1–20
UPDRS part III score 19.7 (12.1) 17.0 1–49
Sex
Male 38 (43.7%) – –
Female 49 (56.3%) – –
Age (years) 78.3 (6.2) 79.0 57–95
Weight (kg) 51.6 (9.7) 49.0 32.0–85.4
AST (IU/L) 24.5 (9.0) 21.0 15–78
ALT (IU/L) 17.5 (10.1) 15.0 6–62
Total bilirubin (mg/dL) 0.64 (0.25) 0.60 0.2–1.4
Albumin (g/dL) 4.1 (0.3) 4.1 3.3–4.7
ALP (IU/L) 265 (103) 253 100–675
Creatinine clearance (mL/min) 56.4 (20.4) 55.0 17.6–118.4
CYP2D6 phenotype
Ultra-rapid metabolizer 2 (2.3%) – –
Extensive metabolizer 58 (66.7%) – –
Intermediate metabolizer 16 (18.4%) – –
Unknowna 11 (12.6%) – –
Administration of concomitant
inhibitors
CYP2D6b 9 (10.3%) – –
CYP3A4c 27
(31.0%)
– –
Administration of concomitant
inducers
CYP3A4d 2 (2.3%) – –
SD, standard deviation; AST, aspartate amino transferase; ALT, alanine amino transferase;
ALP, alkaline phosphatase.
a CYP2D6 genotyping not performed.
b CYP2D6 inhibitors: paroxetine, duloxetine, terbinaﬁne, cimetidine, diltiazem, di-
phenhydramine, ranitidine, and sertraline.
c CYP3A4 inhibitors: clarithromycin, diltiazem, alprazolam, amlodipine, atorvastatin,
cilostazol, cimetidine, ﬂuvoxamine, ketoconazole, and ranitidine.
d CYP3A4 inducers: dexamethasone and pioglitazone.
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mean plasma concentration was proportionally higher in the 10 mg
group than the 5 mg group at Weeks 8 and 12 (the dose was raised to
10mg atWeek 6 in the 10mg group). As a whole, the donepezil plasma
concentration ranged from 6.62–130.9 ng/mL at Week 12 (LOCF).
3.3. Factors affecting plasma donepezil concentration
Prior to multivariate regression analysis, we considered which fac-
tors should be included in the model. The ultra-rapid metabolizer
(n = 2) and poor metabolizer (n = 0) of CYP2D6 phenotypes, andFig. 1. Plasmadonepezil concentration in the 5mg and10mg groups atWeeks 4, 8 and 12.
Error bars indicate the standard deviation. 5 mg group:Week 4, n= 37;Week 8, n= 34;
Week 12, n = 32. 10 mg group: Week 4, n = 48; Week 8, n = 45; Week 12, n = 44. The
10 mg/day dose was administered fromWeek 6 after titration from 3 and 5 mg/day.patients with concomitant use of CYP3A4 inducers (n = 2) were ex-
cluded because of an insufﬁcient number of such patients. AST, ALT,
and total bilirubin were excluded because most of the patients had nor-
mal values. The factors included in the model were the dose, age,
CYP2D6 phenotype and concomitant use of CYP2D6 inhibitor
(Table 2). Creatinine clearance and age were highly correlated; age
was selected for the analysis. The contribution rate of themodel was es-
timated as 0.55 (p b 0.0001), and contributions of dose (contribution
rate: 0.39, p b 0.0001) and of age (contribution rate: 0.12, p = 0.0003)
were statistically signiﬁcant. The observed plasma concentrations in
5 mg and 10 mg-treated patients categorized by age group (b74,
75–80, and N80) are shown in Fig. 2. Mean plasma concentration was
higher in the 10 mg group than the 5 mg group in each age category,
and increased with age (effect of dose: p b 0.001, effect of age: p =
0.015, and interaction term: not signiﬁcant, two-way ANOVA). The ef-
fects of CYP2D6 phenotype and concomitant CYP2D6 inhibitors were
marginally insigniﬁcant.
3.4. Exposure-efﬁcacy analysis
Although the donepezil plasma concentrationwas broadly distribut-
ed in patients with raised MMSE scores, it was relatively low
(b70 ng/mL) in patients whose MMSE score declined. MMSE scores
were either raised or unchanged in all patients with higher plasma
donepezil concentrations (≥70 ng/mL). Plasma donepezil concentration
showed a statistically signiﬁcant positive correlation with changes in
the MMSE score (p = 0.040) (Fig. 3). Similarly, the plasma donepezil
concentration was distributed broadly in patients with an improved
NPI-2 total score, hallucinations score, or cognitive ﬂuctuation score
(Fig. 4A, B, C). The correlationswere not statistically signiﬁcant between
the plasma donepezil concentrations and changes in the parameters
(NPI-2 total score: p = 0.365, hallucinations score: p = 0.616, and cog-
nitive ﬂuctuation score: p= 0.281). Changes in the other NPI items also
did not show a statistically signiﬁcant correlation with the plasma
donepezil concentrations (Delusions: p = 0.242, Agitation/Aggression:
p = 0.634, Depression/Dysphoria: p = 0.891, Anxiety: p = 0.200, Ela-
tion/Euphoria: p = 0.828, Apathy: p = 0.908, Disinhibition: p =
0.521, Irritability/Lability: p = 0.936, Aberrant motor behavior: p =
0.738, and Sleep: p = 0.060).
3.5. Exposure–safety analysis
No correlation was observed between plasma donepezil concentra-
tion and systolic (p = 0.422) or diastolic blood pressure (p = 0.300),
pulse rate (p= 0.433), or bodyweight (p= 0.558) (Fig. 5A–D). Chang-
es in the UPDRS part III total score did not correlate with the plasma
donepezil concentration (p= 0.138). Additionally, patients with wors-
ened UPDRS part III total scores did not show particularly high plasma
donepezil concentrations (Fig. 6).
Values evaluated atWeek 12 (LOCF) are shown. Changes in safety pa-
rameters represent the difference between measurements at baseline
and Week 12 (LOCF). The 10 mg/day dose was administered from
Week 6.Table 2
Factors affecting plasma donepezil concentration according to themultivariate regression
analysis.
Factors Estimate SE p value Contribution
rate
Intercept −93.41 27.69 0.0013
Dose 6.13 0.83 b0.0001 0.386
Age 1.30 0.34 0.0003 0.119
Concomitant CYP2D6 inhibitors (0,
without; 1, with)
12.37 6.76 0.0721 0.027
CYP2D6 phenotype (0, IM; 1, EM) −8.48 4.78 0.0811 0.023
SE, standard error; IM, intermediate metabolizer; EM, extensive metabolizer.
Fig. 2. Observed plasma donepezil concentration by age in patients treated with 5 and
10 mg/day donepezil. Error bars indicate the standard deviation. 5 mg group: b74, n =
9; 75–80, n = 9; N80, n = 11. 10 mg group: b74, n = 14; 75–80, n = 14; N80, n = 10.
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This study, based on data derived from the phase 3 RCT of donepezil,
showed that an increase in plasma donepezil concentration enhanced
its positive effect on cognitive function without compromising safety.
In the phase 2 RCT, 5 and 10 mg of donepezil were sufﬁcient to signiﬁ-
cantly improve MMSE scores compared with the placebo group and
3 mg group [11]. In the phase 3 RCT, 10 mg donepezil signiﬁcantly im-
provedMMSE scores comparedwith the placebo group [9], and increas-
ing the dose to 10 mg from 5 mg further improved the MMSE score in
the subsequent OLE phase [12]. These ﬁndings imply that increasing
plasma donepezil concentration would further improve MMSE scores.
We conﬁrmed this in the present analysis.
Donepezil 23 mg is currently available for moderate to severe AD in
the US and other countries. The ﬁndings of the present study could be
extrapolated to the higher dose; therefore, increasing higher doses
might lead to further improvement of cognitive function also in DLB pa-
tients. Considering that the average weight of the Japanese patients is
less than that of Western countries, this view would be particularly
justiﬁed.
Patients with typical DLB symptoms and fewer concomitant
Alzheimer's features (e.g., presence of hallucinations, larger hippocam-
pal volume, low brain amyloid-β load) are likely to show a greaterFig. 3. Relationship between plasma donepezil concentration and change in MMSE score
(n = 84). MMSE: Mini-Mental State Examination. Values evaluated at Week 12 (LOCF)
are shown. Changes represent the difference between Week 12 (LOCF) and baseline
values. The 10 mg/day dose was administered fromWeek 6.response to ChEIs [25,26]. This may account for the variance of the re-
sponse to donepezil, which weakens plasma concentration–response
relationship.
Compared with the placebo group, the total NPI-2, hallucinations
score, and cognitive ﬂuctuation scores signiﬁcantly improved in pa-
tients treated with 5 mg and 10 mg donepezil, and the improvements
were dose-dependent in the phase 2 RCT [11]. Although PK sampling
was not conducted in the phase 2 RCT, a correlation may have existed
between plasma donepezil concentration and changes in the above
symptoms. In the phase 3 RCT, all neuropsychiatric symptom scores im-
provedwith administration of 5mg and 10mg donepezil, but these im-
provements were not signiﬁcantly different from the placebo group,
owing to an unexpectedly high improvement in the placebo group [9].
Even in the present analysis, correlation of plasma concentration with
NPI-2 scores, hallucinations score, or cognitive ﬂuctuation score was
not apparent. In addition to better non-pharmacological interventions
and coping skills for behavioral and neuropsychological disorders of
DLB possibly applied during the phase 3 RCT [9], expectations or pre-
sumptions of caregivers and examiners in the phase 3 RCT may cause
a positive bias. This is because the NPI is a structured interview given
by the physician to the caregiver, the results of which are likely to be
doubly affected by both examinee and examiner.
In the phase 2 RCT, blood pressure did not decrease in the 10 mg
group, but did decrease in the 5 mg group after 12 weeks of donepezil
treatment. In the phase 3 RCT, with an increasing dose of donepezil,
blood pressure tended to decrease (Supplementary Table 1) and inci-
dence of abnormal blood pressure reduction tended to increase (Sup-
plementary Table 2). However, in the present PK/PD analysis, the
changes in blood pressure were not signiﬁcantly associated with the
plasma donepezil concentration. Therefore, an increase in plasma
donepezil concentration would not necessarily induce a decrement in
blood pressure.
Theoretically, use of ChEIs may increase the risk of bradyarrhythmic
events, towhichDLB patientsmay bemore susceptible than ADpatients
because of disease-speciﬁc autonomic dysfunction [16]. Donepezil ad-
ministration to DLB patients has been reported to increase the risk of
bradyarrhythmic or cardiovascular events [27,17]. In fact, the mean
change at Week 12 from baseline in pulse rate tended to decrease in
the 10 mg group in phase 2 and 3 RCTs and the 5 mg group in the
phase 3 RCT (Supplementary Table 1). However, those studies reported
only one abnormal change in pulse rate in the 10 mg group throughout
the trials (Supplementary Table 2), and changes in pulse rate were not
signiﬁcantly associated with plasma donepezil concentration. These
ﬁndings suggest that higher plasma donepezil concentrations induced
by doses of up to 10 mg/day do not necessarily affect pulse rate or
bradyarrhythmic events. This is consistent with previous investigations
of rivastigmine, which did not affect the incidence of cardiovascular-
related adverse events [28].
Body weight decreased slightly and to a similar extent in the 5 mg
and 10 mg groups, but did not change in the placebo group (Supple-
mentary Table 1). The rate of abnormal weight loss (N7%) did not differ
signiﬁcantly in the 5 and 10 mg groups, but was higher than that of the
placebo group (Supplementary Table 2). Although donepezil treatment
appeared to be correlatedwith reduced bodyweight, this result was not
concentration-dependent, and in fact, changes in body weight showed
no statistically signiﬁcant relationship with the plasma donepezil con-
centration. A decrease in body weight does not always imply an unfa-
vorable effect due to loss of appetite, but could be a favorable effect
due to increase of physical activity. Therefore, if there are no safety con-
cerns including weight loss in patients administered a 5 mg/day dose,
the risk of bodyweight loss may be low in these patients when increas-
ing to 10 mg/day.
Although ChEI treatment can theoretically worsen extrapyramidal
symptoms, the UPDRS part III scores were not signiﬁcantly associated
with the plasma donepezil concentration in the present analysis. This
suggests that increasing the donepezil dose to 10 mg/day would not
Fig. 4. Relationship between plasma donepezil concentration and change in (A) NPI-2 total score, (B) hallucinations score, and (C) cognitive ﬂuctuation score (n = 85). NPI-2:
Neuropsychiatric Inventory-2. Values evaluated at Week 12 (LOCF) are shown. Changes represent differences between baseline and Week 12 (LOCF). The 10 mg/day dose was
administered fromWeek 6.
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though no correlation between plasma concentration and worsening of
parkinsonismwas not demonstrated, it is still important to observe par-
kinsonism during donepezil treatment in these patients.
In the PK analysis, the plasma donepezil concentration was propor-
tional to the administered donepezil dose, in agreement with previous
ﬁndings in healthy volunteers [30]. The mean plasma concentration
was twice higher in patients in the 10 mg group than the 5 mg group,
as expected. Dosewas evidently the largest factor to determine the con-
centration. Considering the relationship between plasma concentration
and safety results, it is worthwhile increasing the dose to 10 mg/day to
increase plasma donepezil concentration for further improving cogni-
tive function. Multivariate regression analysis showed that age was
another signiﬁcant determinant factor. There is a possibility that
the donepezil plasma concentration become relatively low in lower
age group (b74) and relatively high in higher age group (N80). As
for factors of drug metabolism, although the effects of CYP2D6 phe-
notype and concomitant use of CYP2D6 inhibitors were marginal,
type II error was likely because of a small sample size. In addition
to the factors examined in this study, other factors may also inﬂu-
ence the plasma donepezil concentration, such as drug compliance,
interval between dosing and blood sampling, and so on. In any
event, as dose explains only 39%, not only the dose but also various
factors should be taken into consideration when discussing the
dose-response relationship.There are some limitations in the present study. First, as the
sample size was not large, a caution should be paid for statistical
power. Second, the multivariate regression model derived from
the DLB patient population in this analysis may not necessarily be
applicable to other DLB populations, including those that did not
satisfy the inclusion criteria. For example, as patients with severe
dementia of MMSE b 10 or with severe Parkinsonism of Hoehn
and Yahr stage ≥ IV were not included, the ﬁndings are not general-
izable to such patients. Finally, residual covariates may have affect-
ed plasma donepezil concentration, although we explored most of
the generally known covariates.5. Conclusion
The present study demonstrated that plasma donepezil concentra-
tion was affected mainly by dose, although age, possibly genetic factors,
and other unknown factors are also determinants of it. An increase in
plasma donepezil concentration enhances the improvement of cogni-
tive function, not necessarily causing safety parameter worsening,
which is consistent with the dose-response ﬁndings in the previous
trials. For patients without safety concerns after administration of
5 mg/day donepezil, it is worth increasing the dose to 10 mg/day
for the beneﬁts of higher plasma donepezil concentrations on cogni-
tive function.
Fig. 5. Relationship between plasma donepezil concentration and change in (A) systolic blood pressure, (B) diastolic blood pressure, (C) pulse rate, and (D) bodyweight (n= 84). Values
evaluated at Week 12 (LOCF) are shown. Changes in safety parameters represent the difference between measurements at baseline and Week 12 (LOCF). The 10 mg/day dose was
administered fromWeek 6.
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